EcoR1 Capital

EcoR1 Capital is an investment advisory firm focused on the biotech industry. They aim to identify and evaluate innovative therapeutic solutions that can bring significant improvements to patients' lives. Drawing inspiration from the transformative power of the EcoR1 restriction enzyme in the biomedical field, they invest in biotech companies that offer promising new treatments for untreated diseases. EcoR1 Capital recognizes the importance of building upon the innovative contributions of its predecessors in order to continue advancing medical research.

EcoR1 Capital, established in 2012 and headquartered in United States, North America., specializes in Early Stage Venture, Late Stage Venture, Private Equity investments across Biotechnology, Health Care, Medical, Financial Services, Venture Capital, Finance, Non Profit, Therapeutics, Angel Investment, Oncology. The organization boasts a portfolio of 120 investments, with an average round size of $135.8M and 72 successful exits. Their recent investments include Nabriva Therapeutics, Vivo Capital, Wellcome Trust, Novartis Venture Fund, OrbiMed. The highest investment round they participated in was $1845.4B. Among their most notable exits are Nabriva Therapeutics and Vivo Capital. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.